These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21511330)

  • 1. Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
    ; Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A
    Lancet; 2011 May; 377(9777):1580-7. PubMed ID: 21511330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.
    Judd A; Lodwick R; Noguera-Julian A; Gibb DM; Butler K; Costagliola D; Sabin C; van Sighem A; Ledergerber B; Torti C; Mocroft A; Podzamczer D; Dorrucci M; De Wit S; Obel N; Dabis F; Cozzi-Lepri A; García F; Brockmeyer NH; Warszawski J; Gonzalez-Tome MI; Mussini C; Touloumi G; Zangerle R; Ghosn J; Castagna A; Fätkenheuer G; Stephan C; Meyer L; Campbell MA; Chene G; Phillips A;
    HIV Med; 2017 Mar; 18(3):171-180. PubMed ID: 27625109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    Alvarez-Uria G; Pakam R; Naik PK; Midde M
    PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
    Phillips AN; Leen C; Wilson A; Anderson J; Dunn D; Schwenk A; Orkin C; Hill T; Fisher M; Walsh J; Pillay D; Bansi L; Gazzard B; Easterbrook P; Gilson R; Johnson M; Sabin CA;
    Lancet; 2007 Dec; 370(9603):1923-8. PubMed ID: 18068516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
    Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
    JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.
    Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M
    J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.
    Duong T; Judd A; Collins IJ; Doerholt K; Lyall H; Foster C; Butler K; Tookey P; Shingadia D; Menson E; Dunn DT; Gibb DM;
    AIDS; 2014 Oct; 28(16):2395-405. PubMed ID: 25389551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
    Dolling DI; Goodall RL; Chirara M; Hakim J; Nkurunziza P; Munderi P; Eram D; Tumukunde D; Spyer MJ; Gilks CF; Kaleebu P; Dunn DT; Pillay D;
    BMC Infect Dis; 2017 Feb; 17(1):160. PubMed ID: 28222702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
    ; Lodwick R; Costagliola D; Reiss P; Torti C; Teira R; Dorrucci M; Ledergerber B; Mocroft A; Podzamczer D; Cozzi-Lepri A; Obel N; Masquelier B; Staszewski S; García F; De Wit S; Castagna A; Antinori A; Judd A; Ghosn J; Touloumi G; Mussini C; Duval X; Ramos J; Meyer L; Warsawski J; Thorne C; Masip J; Pérez-Hoyos S; Pillay D; van Sighem A; Lo Caputo S; Günthard H; Paredes R; De Luca A; Paraskevis D; Fabre-Colin C; Kjaer J; Chêne G; Lundgren JD; Phillips AN
    Arch Intern Med; 2010 Mar; 170(5):410-9. PubMed ID: 20212176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
    ; ; Costagliola D; Lodwick R; Ledergerber B; Torti C; van Sighem A; Podzamczer D; Mocroft A; Dorrucci M; Masquelier B; de Luca A; Jansen K; De Wit S; Obel N; Fätkenheuer G; Touoloumi G; Mussini C; Castagna A; Stephan C; García F; Zangerle R; Duval X; Pérez-Hoyos S; Meyer L; Ghosn J; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Phillips A
    Lancet Infect Dis; 2012 Feb; 12(2):119-27. PubMed ID: 21988895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
    Boettiger DC; Sudjaritruk T; Nallusamy R; Lumbiganon P; Rungmaitree S; Hansudewechakul R; Kumarasamy N; Bunupuradah T; Saphonn V; Truong KH; Yusoff NKN; Do VC; Nguyen LV; Razali KAM; Fong SM; Kurniati N; Kariminia A
    J Adolesc Health; 2016 Apr; 58(4):451-459. PubMed ID: 26803201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
    Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
    PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.